Imbed Biosciences is committed to providing cutting-edge, evidence-based medical education to advance wound care management, surgical techniques, and clinical solutions. These educational tools are intended to provide healthcare professionals with opportunities to learn about new and developing areas in their field and remain current on recent therapeutic advancements, practices, and procedures.
Clinically Proven Products
In a Prospective Clinical Case Series published in the October 2021 edition of WOUNDS journal, 22 diabetic patients undergoing various surgical procedures were evaluated.
Inclusion Criteria: Diabetic patients – a 13% historical SSI rate. The study’s primary objective was to decrease this rate to 6.5% by prophylactic treatment using Surgaflex™
Procedure: Surgical procedures included amputation, removal of exostosis, midfoot bone removal, Achilles’ tendon repair, bunionectomy, or an elevating osteotomy with primary closure of the wound. Patients were assessed on day 3 or 5 for SSI incidence and followed for 90 days.
Results: The per-protocol patient population (20/22) had a 0% SSI rate with healing times typical to the procedure (between 10 and 34 days). Two patients were not included in the analysis due to non-compliance.9
Published clinical data in the November 2020 edition of WOUNDS journal shows the clinical results of using Microlyte® Matrix for chronic wounds. Thirty-two patients with various chronic wounds were evaluated. All wounds were non-healing for a median of 39 weeks (range, 3-137 weeks).
At 3 weeks: 79% closure in responsive DFU patients. 60% closure in responsive venous stasis ulcers. 72% of all wounds had significantly improved healing with an average wound area reduction of 66%.
At 12 weeks: 91% of wounds either healed completely or improved significantly with an average wound area reduction of 73%.
The application of Microlyte® Matrix was safe and well tolerated, and it facilitated improvements in healing of a majority of the complex chronic wounds studied.8